Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Atumelnant (Crinetics CRNX) Could Redefine Congenital Adrenal Hyperplasia Treatment

Understanding Congenital Adrenal Hyperplasia and Its Treatment Challenges

Nitish Kishor | 07 July 2026

Why Cosmos Health (NASDAQ: COSM) Is Using a Buyback to Signal Undervaluation

The Strategic Logic of Buybacks in Micro-Cap Healthcare

Nitish Kishor | 07 July 2026

Why Aurinia Pharmaceuticals (NASDAQ: AUPH) Commenced a LUPKYNIS Phase 4 Trial

Lupus Nephritis and LUPKYNIS's Commercial Position

Nitish Kishor | 07 July 2026

Why TG Therapeutics (NASDAQ: TGTX) Rose 4% on Schizophrenia Trial Launch

The Neuroinflammatory Hypothesis for Schizophrenia

Nitish Kishor | 07 July 2026

Why the VRTX-CRNX Deal Reset Rare Endocrinology M&A Valuations

Decoding the Valuation Multiple in the Crinetics Deal

Nitish Kishor | 07 July 2026

Why Vaxart Inc. (NASDAQ: VXRT) Dipped 3.6% Despite Clean Vaccine Safety Data

The Oral COVID Vaccine Platform and What It Promises

Nitish Kishor | 07 July 2026

Why Pharvaris N.V. (NASDAQ: PHVS) Edged Down 1.9% Approaching PDUFA Date

Hereditary Angioedema and the On-Demand Treatment Market

Nitish Kishor | 07 July 2026
Support

Hi! How can we help you today?

Loading…